Evotec SE Joins NURTuRE-AKI Consortium to Enhance Kidney Disease Research and Innovation

### Evotec SE Joins NURTuRE-AKI Consortium to Advance Kidney Disease Research

Evotec SE announces its membership in the NURTuRE-AKI consortium, a significant collaborative effort aimed at addressing acute kidney injury (AKI) through innovative therapeutic approaches. This consortium brings together various organizations focused on enhancing research and development in the field of nephrology. By joining forces with other key players, Evotec seeks to expand its capabilities in drug discovery and development, reinforcing its commitment to tackling unmet medical needs associated with kidney diseases. The rising incidence of kidney-related disorders globally makes this initiative particularly timely and relevant.

The strategic partnership with NURTuRE-AKI allows Evotec to leverage shared knowledge and resources, fostering an environment conducive to groundbreaking research. By pooling expertise from multiple stakeholders, the consortium aims to accelerate the discovery of new therapeutic solutions for AKI, a condition that poses significant challenges in clinical settings. This collaboration is expected to enhance Evotec's position as a frontrunner in biopharmaceutical innovation, particularly in the nephrology arena, where advances can lead to improved patient outcomes.

The market's positive response to Evotec's announcement indicates strong investor confidence in the company's strategic direction and its potential to contribute meaningfully to kidney disease treatments. As the consortium embarks on its mission, Evotec's involvement underscores the company’s proactive approach in the biopharmaceutical landscape, signifying a commitment to harnessing collaborative research for the benefit of patients suffering from renal disorders.

### Additional Developments

In related news, Evotec SE continues to explore various initiatives that align with its focus on innovation in healthcare. The company remains dedicated to expanding its research capabilities and partnerships, which are crucial for enhancing drug development processes across multiple therapeutic areas.

As the company engages with the NURTuRE-AKI consortium, it signals a robust response to the increasing global demand for effective therapies in nephrology, showcasing its dedication to driving advancements in the biopharmaceutical sector.